Bio-protocol

Bio-protocol (ISSN: 2331-8325) is an e-journal created in 2011 by a group of Stanford researchers. Our mission is to make life science research more efficient and reproducible by curating high quality, open-access, life science protocols. We differ from other journals and online protocol depositories in a number of ways. We are free to publish with and we are free to use. Our protocols are of the highest quality because publication is by invitation only, and all of our articles undergo extensive peer review to ensure reproducibility.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

SPOTLIGHT THERAPEUTICS CLOSES ITS SERIES A FINANCING BRINGING THE TOTAL RAISED TO $30 MILLION

Spotlight Therapeutics | December 01, 2020

news image

Spotlight Therapeutics, Inc., a biotechnology organization creating non-viral quality altering therapeutics for direct in vivo altering of target genes, closed its Series A financing bringing the complete raised to $30 million. The financing was driven by GV, in the past Google Ventures, with interest from extra undisclosed investors. Realizing the full revolutionary potential of CRISPR genome editing requires the ability to edit target genes directly in the right cells of the hum...

Read More

DIAGNOSTICS

EVONETIX GRANTED PATENT FOR TECHNOLOGY ENABLING THERMALLY-CONTROLLED DNA SYNTHESIS

evonetix | April 04, 2022

news image

EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has been granted patent EP3551331B1 in Europe for its proprietary thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips. This patent extends Evonetix’s IP portfolio and is a key step in the Company’s strategy to develop a benchtop DNA synthesis platform, to change how DNA is accessed, made, and u...

Read More

SMART MONEY IS RACING INTO THE BIOTECH BOOM

FN Media Group | May 08, 2020

news image

The biotech boom is back. After its big breakthrough a few years ago, the biotech industry fell silent. Now, it is in the spotlight once again as smart money races in to back some once-in-a-generation breakthroughs. Mentioned in today's commentary includes: CRISPR Therapeutics AG (NASDAQ: CRSP), Sangamo Therapeutics, Inc. (NASDAQ: SGMO), Microsoft Corporation (NASDAQ: MSFT), International Business Machines Corporation (NYSE: IBM), Apple Inc. (NASDAQ: AAPL).From exciti...

Read More

LILLY BEGINS WORLD'S FIRST STUDY OF A POTENTIAL COVID-19 ANTIBODY TREATMENT IN HUMANS

Lilly | June 01, 2020

news image

Eli Lilly and Company (NYSE: LLY) today announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19.This investigational medicine, referred to as LY-CoV555, is the first to emerge from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in just three months after AbCellera and the Vaccine Research Center at t...

Read More
news image

CELL AND GENE THERAPY

SPOTLIGHT THERAPEUTICS CLOSES ITS SERIES A FINANCING BRINGING THE TOTAL RAISED TO $30 MILLION

Spotlight Therapeutics | December 01, 2020

Spotlight Therapeutics, Inc., a biotechnology organization creating non-viral quality altering therapeutics for direct in vivo altering of target genes, closed its Series A financing bringing the complete raised to $30 million. The financing was driven by GV, in the past Google Ventures, with interest from extra undisclosed investors. Realizing the full revolutionary potential of CRISPR genome editing requires the ability to edit target genes directly in the right cells of the hum...

Read More
news image

DIAGNOSTICS

EVONETIX GRANTED PATENT FOR TECHNOLOGY ENABLING THERMALLY-CONTROLLED DNA SYNTHESIS

evonetix | April 04, 2022

EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has been granted patent EP3551331B1 in Europe for its proprietary thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips. This patent extends Evonetix’s IP portfolio and is a key step in the Company’s strategy to develop a benchtop DNA synthesis platform, to change how DNA is accessed, made, and u...

Read More
news image

SMART MONEY IS RACING INTO THE BIOTECH BOOM

FN Media Group | May 08, 2020

The biotech boom is back. After its big breakthrough a few years ago, the biotech industry fell silent. Now, it is in the spotlight once again as smart money races in to back some once-in-a-generation breakthroughs. Mentioned in today's commentary includes: CRISPR Therapeutics AG (NASDAQ: CRSP), Sangamo Therapeutics, Inc. (NASDAQ: SGMO), Microsoft Corporation (NASDAQ: MSFT), International Business Machines Corporation (NYSE: IBM), Apple Inc. (NASDAQ: AAPL).From exciti...

Read More
news image

LILLY BEGINS WORLD'S FIRST STUDY OF A POTENTIAL COVID-19 ANTIBODY TREATMENT IN HUMANS

Lilly | June 01, 2020

Eli Lilly and Company (NYSE: LLY) today announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19.This investigational medicine, referred to as LY-CoV555, is the first to emerge from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in just three months after AbCellera and the Vaccine Research Center at t...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us